Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,482
  • Shares Outstanding, K 23,258
  • Annual Sales, $ 10,640 K
  • Annual Income, $ -51,450 K
  • 60-Month Beta 3.70
  • Price/Sales 17.20
  • Price/Cash Flow N/A
  • Price/Book 1.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.81
  • Number of Estimates 3
  • High Estimate -0.75
  • Low Estimate -0.85
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.07 +9.19%
on 03/12/19
9.03 -14.51%
on 03/04/19
-0.36 (-4.46%)
since 02/25/19
3-Month
3.74 +106.42%
on 12/31/18
9.03 -14.51%
on 03/04/19
+3.51 (+83.37%)
since 12/24/18
52-Week
3.74 +106.42%
on 12/31/18
38.82 -80.11%
on 03/28/18
-27.28 (-77.94%)
since 03/23/18

Most Recent Stories

More News
Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company's...

MNLO : 7.72 (-0.52%)
Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has...

MNLO : 7.72 (-0.52%)
ALDR : 13.24 (+2.28%)
Menlo Therapeutics to Present at the 31st Annual ROTH Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present...

MNLO : 7.72 (-0.52%)
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 7.72 (-0.52%)
Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that an abstract has been...

MNLO : 7.72 (-0.52%)
Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Incyte Corporation (NASDAQ:INCY),...

MNLO : 7.72 (-0.52%)
BURL : 145.62 (-0.25%)
INCY : 86.02 (+0.80%)
IRBT : 120.47 (+1.02%)
LEA : 133.63 (+1.14%)
HASI : 25.26 (+0.60%)
Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: MNLO shares over alleged securities laws violations by Menlo Therapeutics Inc. in connection with the...

MNLO : 7.72 (-0.52%)
Lawsuit for Investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / December 17, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) over alleged...

MNLO : 7.72 (-0.52%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 7.72 (-0.52%)
Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apptio Inc. (NASDAQ:APTI),...

MNLO : 7.72 (-0.52%)
CDR : 3.40 (+1.49%)
TOL : 36.46 (+2.82%)
IIVI : 36.83 (+0.99%)
APTI : 37.97 (-0.03%)
SKT : 20.53 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MNLO with:

Business Summary

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic...

See More

Key Turning Points

2nd Resistance Point 8.19
1st Resistance Point 7.98
Last Price 7.72
1st Support Level 7.57
2nd Support Level 7.37

See More

52-Week High 38.82
Fibonacci 61.8% 25.42
Fibonacci 50% 21.28
Fibonacci 38.2% 17.14
Last Price 7.72
52-Week Low 3.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar